Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412331 | 0.92 | USP30 (0.51) | USP30GPR119CRBNEGFRSRC | |
| SCHEMBL4407107 | 0.87 | MAPK1 (0.44) | USP30GPR119ABCB1 | |
| SCHEMBL4418602 | 0.85 | RIPK1 (0.46) | USP30 | |
| SCHEMBL4411026 | 0.85 | USP30 (0.40) | USP30 | |
| SCHEMBL4409890 | 0.84 | MTNR1A (0.44) | EGFRSRC | |
| SCHEMBL4407499 | 0.83 | MAPT (0.41) | GPR119 | |
| SCHEMBL4410030 | 0.81 | LMNA (0.39) | USP30GPR119 | |
| SCHEMBL4406534 | 0.80 | ESR2 (0.40) | USP30GPR119 | |
| SCHEMBL4410917 | 0.80 | USP30 (0.49) | USP30GPR119CRBNEGFRSRC | |
| SCHEMBL3277263 | 0.79 | PIK3CA (0.60) | USP30GPR119PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | USP30 4369/4885GPR119 234/4885CRBN 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.